Literature DB >> 9199968

Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma.

W Rudy1, B Gückel, M Siebels, M Lindauer, S C Meuer, U Moebius.   

Abstract

Introduction of co-stimulatory molecules like CD80 and CD86 represents a means to augment the immunogenicity of tumor cells and to induce immune responses directed at tumor antigens. Here we compared CD80- and CD86-transfected human melanoma cells to induce primary immune responses by their capacity to promote proliferation of human allogeneic resting T lymphocytes. CD80- and CD86-transfected SkMel63 melanoma cells induced T cell activation to a comparable degree, which was found to be independent of the cell surface density of these co-stimulatory molecules. Co-expression of CD80 and CD86 did not result in a synergistic increase in T cell proliferation. Both CD80 and CD86 transfectants induced the proliferation of isolated CD4+ or CD8+ T cells. Exogenous IL-2, IL-4 and tumor necrosis factor-alpha respectively enhanced primary T cell proliferation independent of CD80 or CD86 expression. Interestingly, differential activities of CD80 and CD86 were observed following stimulation of resting T cells in the presence of IL-12. Whereas IL-12 increased T cell proliferation in the presence of CD86-transfected melanoma cells, it exhibited an inhibitory function in the presence of CD80-expressing SkMel63 cells. Experimental evidence indicates that this inhibitory effect was mediated by IFN-gamma since (I) IFN-gamma secretion of stimulated T cells was augmented by IL-12, (II) exogenous IFN-gamma also inhibited T cell proliferation induced by CD80- but not CD86-transfected SkMel63 cells and (III) the inhibitory effect of IL-12 was blocked by an anti-IFN-gamma mAb.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9199968     DOI: 10.1093/intimm/9.6.853

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  4 in total

1.  Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.

Authors:  S J Pettit; S Ali; E O'Flaherty; T R Griffiths; D E Neal; J A Kirby
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Gene transfer of costimulatory molecules into a human colorectal cancer cell line: requirement of CD54, CD80 and class II MHC expression for enhanced immunogenicity.

Authors:  M Lindauer; W Rudy; B Gückel; M V Doeberitz; S C Meuer; U Moebius
Journal:  Immunology       Date:  1998-03       Impact factor: 7.397

3.  A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors.

Authors:  Philip Eliades; David M Miller; Benchun Miao; Raj Kumar; Michael Taylor; Shama Buch; Sreesha P Srinivasa; Keith T Flaherty; Hensin Tsao
Journal:  Cancer Biol Ther       Date:  2016-07-02       Impact factor: 4.742

Review 4.  The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells.

Authors:  Guranda Chitadze; Ulrike Wehkamp; Ottmar Janssen; Monika Brüggemann; Marcus Lettau
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.